Alpha BreakingDCG: Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
|Thursday, May 14, 2026 at 1:01 PM ET
Share this article
Spread the word on social media
Latest Updates
May 14, 3:48 PM
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global precision oncology company, today...
Source: PR Newswire
May 14, 3:39 PM
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global precision oncology company, today...
Source: PR Newswire